Review Article
A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases
Table 2
Summary of results for systemic therapy of neuroendocrine tumour liver metastases.
| Modality author [Ref] | Intervention | Number of patients | Overall survival (5 years) | Median survivals (months) | Progression/disease-free survival | Clinical response | Biochemical response | Radiological response |
| Biological Therapy | | | | | | | | |
| Ducreux et al. [26] | Lantreotide | 46 | | | | | | 5% | Aparicio et al. [27] | Octreotide | 35 | | | 11 months | | | 3% (57% stabilised) | Rinke et al. [28] | Octreotide LAR | 85 | | | 14.3 months | | | 67% stabilised | Oberg and Eriksson [29] | IFN α | 111 | | >80 | 34 months | 68% | 42% | 15% (39% stabilised) | Arnold et al. [30] |
OctreotidFN α | 109 | | 32 versus 54 (combined) | | | | 1.9% (27% stabilised) | Fjällskog et al. [31] |
SomatostatiFN α | 16 | | | | | 62.5% | 19% |
| Chemotherapy | | | | | | | | |
| Moertel et al. [32] | SToxorubicin | 36 | | 26 | 20 months | | | 69% | | STFU | 33 | | 18 | 6.9 months | | | 45% | Turner et al. [33] | 5FisplatiTZ | 79 | | 31.5 | 9.1 months | | | 33% | Sun et al. [34] | SToxorubicin | 85 | | 15.7 | 4.5 months | | | 15.9% | | STFU | 78 | | 24.3 | 5.3 months | | | 16% | Kouvaraki et al. [35] | 5FoxorubiciTZ | 61 | 74% (2 yrs) | | 41% (2 years) | | | | Strosberg et al. [36] | Temolozomidapecitabine | 30 | 92% (2 yrs) | | 18 months | | | 70% | Moertel et al. [37] | Etoposidisplatin | 18 | | 19 | 8 months | | | 67% |
| Molecular-targeted therapy | | | | | | | | |
| Raymond et al. [38] | Sunitinib | 171 | | | 11.4 months | | | 9.3% | Yao et al. [39] | Everolimus | 410 | 34% (1.5 yrs) | | 11 months | | | | Yao et al. [40] | Bevacizumab | 44 | | | 95% (18 weeks) | | | |
| PPRT | | | | | | | | |
| Cwikla et al. [41] | DOTATATE Y-90 | 60 | | 22 | 17 months | 72% | | 23% | Kwekkeboom et al. [42] | 177Lu-octreotate | 131 | | | >36 months | | | 28% | Pfeifer et al. [43] | Y-DOTATOC or 177Lu-DOTATOC | 69 | | | 29 months | | | 23.6% | Kwekkeboom et al. [44] | 177Lu-DOTA 0,Tyr3 | 310 | | 46 | 40 months | | | 30% |
|
|